Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Divarasib vs KRAS G12C inhibitors in previously treated KRAS G12C-positive NSCLC
2024-510908-37-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of divarasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-510908-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510908-37-00.